Logo

IFN-γ, CXCL16, uPAR: potential biomarkers for systemic lupus erythematosus

1, 2, 3, 4, 5, 6

  1. Department of Nephrology, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
  2. Department of Nephrology, Jiangmen Central Hospital, Affiliated Jiangmen Hospital of Sun Yat-Sen University, Jiangmen, Guangdong, China.
  3. Department of Nephrology, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China. zhuxuejing5225209@163.com
  4. Department of Nephrology, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
  5. Department of Nephrology, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
  6. Department of Nephrology, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China.

CER10071 Submission on line
Full Papers

Rheumatology Article

 

Abstract

OBJECTIVES:
IFN-γ, CXCL16 and uPAR have recently been regarded as potential biomarkers in systemic lupus erythematosus (SLE). However, few researches have focused on the comparison of these three markers in SLE. We conducted this study to evaluate their role as biomarkers of disease activity and renal damage.
METHODS:
We enrolled 50 SLE patients with or without lupus nephritis (LN) and 15 healthy control subjects. The levels of IFN-γ, CXCL16, uPAR in serum, urine and renal tissues were detected by ELISA or immunohistochemistry. Relevant clinical and laboratory features were recorded.
RESULTS:
Serum and urine IFN-γ, CXCL16 and suPAR levels in SLE patients were significantly higher than that in healthy controls. Moreover, LN patients had higher levels than non-LN patients. A positive correlation was observed between these markers, and disease activity and suPAR had a stronger association with disease activity. The expression of these biomarkers in renal tissues was significantly higher in LN patients and was also associated with the activity of pathological lesions.
CONCLUSIONS:
IFN-γ, CXCL16 and uPAR are promising as effective biomarkers of disease activity, renal damage, and the activity of pathological lesions in SLE.

PMID: 28628472 [PubMed]

Received: 05/11/2016 - Accepted : 05/04/2017 - In Press: 16/06/2017